pirfenidone has been researched along with carboplatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, A; Funaki, S; Kawamura, T; Kimura, T; Minami, M; Okumura, M; Shintani, Y | 1 |
| Akazawa, Y; Ishijima, M; Kanazu, M; Kuge, T; Mori, M; Okabe, F; Uenami, T; Yamaguchi, T; Yamamoto, Y; Yano, Y | 1 |
| Antunes, C; Branco, H; Oliveira, J; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
3 other study(ies) available for pirfenidone and carboplatin
| Article | Year |
|---|---|
Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Fibroblasts; Humans; Lung Neoplasms; Mice; Phosphorylation; Pyridones; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1 | 2017 |
Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Idiopathic Pulmonary Fibrosis; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Pyridones; Retrospective Studies | 2020 |
Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin.
Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Humans; Lung Neoplasms; Paclitaxel; Pyridones | 2022 |